BorisDJuelgMD
Infectious Disease • Boston, MAClinical Fellow in Medicine, Massachusetts General Hospital
Dr. Juelg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114Phone+1 617-726-2865Fax+1 617-724-8761
Education & Training
Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 2012 - 2014- Massachusetts General HospitalResidency, Internal Medicine, 2010 - 2012
Univ Kiel- Christian- Albrechts- Fac MedClass of 2003
Certifications & Licensure
MA State Medical License 2015 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults Start of enrollment: 2016 Nov 01
- A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults Start of enrollment: 2018 Dec 03
Publications & Presentations
PubMed
- 9 citationsDifferences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination.Vicky Roy, Wonyeong Jung, Caitlyn Linde, Emily Coates, Julie Ledgerwood
NPJ Vaccines. 2023-03-15 - 12 citationsAntibody-Invertase Fusion Protein Enables Quantitative Detection of SARS-CoV-2 Antibodies Using Widely Available Glucometers.Elissa K Leonard, Miguel Aller Pellitero, Boris Juelg, Jamie B Spangler, Netzahualcóyotl Arroyo-Currás
Journal of the American Chemical Society. 2022-06-29 - 25 citationsDissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022.Caroline Atyeo, Matthew D. Slein, Stephanie Fischinger, John F. Burke, Alexandra Schäfer
JCI Insight. 2021-01-11
Press Mentions
Promising Results of Triple Antibody Therapy for Long-Term HIV Control: Randomized Trial FindsSeptember 14th, 2024- Medical Bulletin 14/ September/ 2024September 13th, 2024
- Triple Antibody Therapy Shows Promise for Long-Lasting HIV ControlSeptember 13th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
